ISRCTN88008850已完成不适用
A phase III, randomised, multicentre, dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a with Child's A or B cirrhosis in Chronic Hepatitis C virus infectio
Southampton University Hospitals NHS Trust (UK)0 个研究点目标入组 100 人开始时间: 2005年10月25日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •To be eligible for this trial, patients must have documentation of the following:
- •1. Aged over 18 years
- •2. Serologic evidence of Hepatitis C Virus (HCV) infection by an anti-HCV antibody test
- •3. Qualitative evidence of infection with HCV Ribonucleic Acid (RNA)
- •4. Chronic liver disease consistent with chronic hepatitis C infection on a biopsy as judged by a local pathologist
- •5. Patients must have had an abdominal ultrasound, Computed Tomography (CT) scan, or Magnetic Resonance Imaging (MRI) scan with evidence of cirrhosis, but without evidence of hepatocellular carcinoma (within two months of randomisation) and a serum alphafetoprotein (AFP) less than 100 ng/ml. Patients with elevated AFP should have evidence of no increase of more than 10 KIU/l for three months prior to entry
- •6. Negative urine pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of test drug. Additionally, all fertile male patients, male patients with female partners of childbearing age, and females must be using two reliable forms of effective contraception during the study
排除标准
- •Patients with any of the following will not be eligible for participation:
- •1. Patients who are expected to need systemic antiviral therapy at any time during their participation in the study are excluded. Exception: patients who have had a limited (seven day) course of acyclovir or alcyclovir for herpetic lesions more than one month prior to the first administration of test drug are not excluded
- •2. Positive test at screening for anti-Hepatitis A Virus (anti-HAV) Immunoglobulin M (IgM) antibody (Ab), Hepatitis B surface Antigen (HBsAg), anti-Hepatitis B core (anti-HBc) IgM Ab, or anti-Human Immunodeficiency Virus (anti-HIV) Ab
- •3. Documented serum concentrations of ceruloplasmin or a1-antitrypsin consistent with an increased risk of metabolic liver disease
- •4. History or other evidence of a medical condition associated with chronic liver disease (e.g. hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures)
- •5. Women with ongoing pregnancy or breast feeding
- •6. Decompensated liver disease within the last three months
- •7. Neutrophil count less than 1500 cells/mm^3, Hgb less than 12 g/dl in women or 13 g/dl in men, or platelet count less than 60,000 cells/mm^3
- •8. Any patient with a baseline increased risk for anemia (e.g. thalassemia, spherocytosis, history of gastrointestinal [GI] bleeding etc.) or for whom anemia would be medically problematic
- •9. Serum creatinine level more than 1.5 times the upper limit of normal at screening
- •10. Patients unlikely to comply with the study schedule due to alcohol and/or drug abuse
- •11. History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least three months at any previous time or any history of the following: a suicidal attempt, hospitalisation for psychiatric disease, or a period of disability due to a psychiatric disease
- •12. History of immunologically mediated disease (e.g. inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis requiring more than intermittent nonsteroidal anti-inflammatory medications for management etc.)
- •13. History or other evidence of chronic pulmonary disease associated with functional limitation
- •14. History of a severe seizure disorder or current anticonvulsant use
- •15. Evidence of an active or suspected cancer or a history of malignancy where the risk of recurrence is more than 20% within two years. Patients with a lesion suspicious for hepatic malignancy on the screening imaging study will only be eligible if the likelihood of carcinoma is less than 10% following an appropriate evaluation
- •16. History of having received any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) less than six months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study
- •17. History of major organ transplantation with an existing functional graft
- •18. History of thyroid disease poorly controlled on prescribed medications. Patients with elevated thyroid stimulating hormone concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease are excluded
- •19. History or other evidence of severe retinopathy
研究者
相似试验
进行中（未招募）
1 期
A phase III, randomised, mulicentre dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child's A or B cirrhosis in chronic hepatitis C virus infection. - PACIFIC StudyHepatic cirrhosis due to Chronic Hepatitis C virus (HCV) infectionEUCTR2004-000417-18-GBSouthampton University Hospitals NHS Trust100
进行中（未招募）
1 期
To see how the medication MED2005 works (i.e. causes an erection) compared to placebo when applied to the penis by male volunteers who normally are unable to obtain an erectioEUCTR2017-000960-14-HUFutura Medical Developments Ltd.1,000
进行中（未招募）
1 期
To see how the medication MED2005 works (i.e. causes an erection) compared to placebo when applied to the penis by male volunteers who normally are unable to obtain an erectioEUCTR2017-000960-14-PLFutura Medical Developments Ltd.1,000
进行中（未招募）
1 期
To see how the medication MED2005 works (i.e. causes an erection) compared to placebo when applied to the penis by male volunteers who normally are unable to obtain an erectioErectile dysfunctionMedDRA version: 20.0Level: PTClassification code 10061461Term: Erectile dysfunctionSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: LLTClassification code 10015116Term: Erectile disturbanceSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: LLTClassification code 10025503Term: Male erectile disorderSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: LLTClassification code 10052003Term: Erectile dysfunction NOSSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2017-000960-14-LVFutura Medical Developments Ltd.1,000
进行中（未招募）
1 期
To see how the medication MED2005 works (i.e. causes an erection) compared to placebo when applied to the penis by male volunteers who normally are unable to obtain an erectioEUCTR2017-000960-14-SKFutura Medical Developments Ltd.1,000